fbpx
Darren G. Woodside, PhD

Darren Woodside, Ph.D., is the Vice President for Research and Director of the Flow Cytometry and Imaging Core at the Texas Heart Institute. Show full bio

Dr. Woodside’s research centers around the role that cell adhesion plays in cardiovascular and autoimmune diseases, and the development of novel means to identify and treat these diseases. Prior to assuming the position of Vice President, he served as Associate Director of the Molecular Cardiology Research Laboratories at THI and Associate Director of Drug Discovery at Encysive Pharmaceuticals. He was awarded his Ph.D. from the University of Texas MD Anderson Cancer Center’s Department of Immunology and was a post-doctoral fellow at The Scripps Research Institute.

He has authored numerous publications, served on Editorial Review Boards, and currently chairs the NIH Innovative Immunology Study Section.

See Publications

Texas Heart Institute Positions

Interests

Education

  • Undergraduate:

    Queen's University at Kingston

  • Postgraduate:

    University of Texas MD Anderson Cancer Center, Graduate School of Biomedical Sciences

  • Fellowships:

    The Scripps Research Institute

Honors, Awards and Memberships

Publications

Pogostin, B. H., Yu, M. H., Azares, A. R. et al. (2022). Multidomain peptide hydrogel adjuvants elicit strong bias towards humoral immunity. Biomater Sci. https://doi.org/10.1039/d2bm01242a.
Hickman, A., Koetsier, J., Kurtanich, T. et al. (2022). LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade. J Clin Invest 132, e154152. https://doi.org/10.1172/JCI154152.
Lokugamage, N., Chowdhury, I. H., Biediger, R. J. et al. (2021). Use of a small molecule integrin activator as a systemically administered vaccine adjuvant in controlling Chagas disease. NPJ Vaccines 6, 114. https://doi.org/10.1038/s41541-021-00378-5.
Lopez-Silva, T. L., Leach, D. G., Azares, A. et al. (2020). Chemical functionality of multidomain peptide hydrogels governs early host immune response. Biomaterials 231, 119667. https://doi.org/10.1016/j.biomaterials.2019.119667.
Bakthavatsalam, D., Craft, J. W., Kazansky, A. et al. (2020). Identification of Inhibitors of Integrin Cytoplasmic Domain Interactions With Syk. Front Immunol 11, 575085. https://doi.org/10.3389/fimmu.2020.575085.
Woodside, D. G. (2019). Nanoparticle imaging of vascular inflammation and remodeling in atherosclerotic disease. Current Cardiovascular Imaging Reports 12. https://doi.org/10.1007/s12410-019-9501-9.
Woodside, D. G., Tanifum, E. A., Ghaghada, K. B. et al. (2018). Magnetic resonance imaging of atherosclerotic plaque at clinically relevant field strengths (1T) by targeting the integrin α4β1. Sci Rep 8, 3733. https://doi.org/10.1038/s41598-018-21893-x.
Kumar, V. A., Liu, Q., Wickremasinghe, N. C. et al. (2016). Treatment of hind limb ischemia using angiogenic peptide nanofibers. Biomaterials 98, 113–119. https://doi.org/10.1016/j.biomaterials.2016.04.032.
Deng, Y., Yang, Z., Terry, T. et al. (2016). Prostacyclin-producing human mesenchymal cells target H19 lncRNA to augment endogenous progenitor function in hindlimb ischaemia. Nat Commun 7, 11276. https://doi.org/10.1038/ncomms11276.
Bakthavatsalam, D., Soung, R. H., Tweardy, D. J. et al. (2014). Chaperonin-containing TCP-1 complex directly binds to the cytoplasmic domain of the LOX-1 receptor. FEBS Lett 588, 2133–2140. https://doi.org/10.1016/j.febslet.2014.04.049.

Recent News

See All

7 Hills Pharma Announces First Patient in Phase 1b/2a Clinical Trial Testing Alintegimod Against aPD-1-resistant Solid Tumors

The Texas Heart Institute is excited to share the groundbreaking progress of 7 Hills Pharma Inc. (“7 Hills”), a clinical-stage...

Read more

Bringing Together the Best of Cardiovascular Science: The Texas Heart Institute Hosts 11th Annual IACS-NAS Meeting

Demonstrating its continued commitment to innovation in cardiovascular science and medicine, The Texas Heart Institute recently hosted the 11th Annual...

Read more

A Discovery by The Texas Heart Institute & 7 Hills Pharma Continues Development under a $4.7 Million CPRIT Grant to Address Cancer Treatment Disparities

Peter Vanderslice, PhD, Senior Investigator and Director, MCRL, Molecular Cardiology Research, was highlighted in a recent announcement from 7 Hills Pharma,...

Read more